Aspiration pneumonia bacterial infection: Difference between revisions
| Line 48: | Line 48: | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
==Natural History, Complications and Prognosis== | ==Natural History, Complications and Prognosis== | ||
* [[Lung abscess]] | * [[Lung abscess]] | ||
Revision as of 19:21, 8 September 2012
| Aspiration pneumonia bacterial infection | ||
| ICD-10 | J12, J13, J14, J15, J16, J17, J18, P23 | |
|---|---|---|
| ICD-9 | 480-486, 770.0 | |
| DiseasesDB | 10166 | |
| MeSH | pneumonia bacterial infection&field=entry#TreeC08.381.677 C08.381.677 | |
|
Aspiration pneumonia bacterial infection Microchapters |
|
Differentiating Aspiration pneumonia bacterial infection from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Aspiration pneumonia bacterial infection On the Web |
|
American Roentgen Ray Society Images of Aspiration pneumonia bacterial infection |
|
Directions to Hospitals Treating Aspiration pneumonia bacterial infection |
|
Risk calculators and risk factors for Aspiration pneumonia bacterial infection |
For patient information click here
Editor(s)-in-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753; Associate Editor(s)-In-Chief: Priyamvada Singh, M.D. [2]
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Aspiration pneumonia bacterial infection from other Diseases
Epidemiology and Demographics
Risk factors
Natural History, Complications and Prognosis
Prognosis predictor scores: CURB-65 | Aspiration pneumonia bacterial infection severity index | Criteria for severe community acquired Aspiration pneumonia bacterial infection
Diagnosis
Diagnostic criteria | History and Symptoms | Physical Examination | Laboratory Findings | Chest X Ray
Treatment
Natural History, Complications and Prognosis
Risk factors
- Poor dental hygiene is a risk factor
- Patients with good dental hygiene and edentulous are less predisposed
Treatment
Medical therapy
Antibiotics
- Treatment of choice clindamycin
- Doses 600 mg Q8hourly, followed by 300 mg Q6hourly, or 450 mg tid
- Advantage of clindamycin :
- Cheap
- Less incidences of superimposed MRSA
- Other agents used: Ampicillin-sulbactam (1.5 g or 3 g twice daily), Imipenem (Invanz 500 mg BID), amoxicillin-clavulnate (875 mg orally bid), penicillin (1 to 2 million units IV Q6hourly) / amoxicillin (500 mg orally tid)+ metronidazole (500 mg orally or IV tid).
- Monotherapy with metronidazole is not preferred as high failure rates have been reported. This is because metronidazole is ineffective against some pathogens such as microaerophilic and aerobic streptococci